glp 1/gip agonist The activity of GLP-1 and GIP for Type 2 Diabetes and Obesity GLP1-GIP receptor co-agonists: a promising
Description
Muscogiuri, G., DeFronzo, R
Tirzepatide was approved by the Food and Drug Administration in May 2022 for the treatment of T2D, and later in October received Fast Track designation for treatment of obesity
Kosiborod, M
Researchers established an alarming trend of GLP-1RA misuse in exercise populations that carries significant public health implications
10.1186/s40478-019-0695-5 Acta Neuropathol
